Irbesartan and Atenolol in Hypertensive Heart Disease (SILVHIA)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure.
This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
Full description
We included 115 patients with hypertension and cardiac hypertrophy, established by echocardiography. Extensive echocardiographic examinations, ultrasonography of the carotid arteries, 24h Holter registrations, 24h ambulatory blood pressure monitoring monitoring, neurohormones and blood samples for inflammation and hemostasis markers and endothelial function were done at weeks 0, 12, 24, and 48. Matched control groups (1:3, i.e. 38 normotensive subjects and 38 hypertensive subjects with no signs of hypertensive heart disease were examined at one occasion. All patients obtained irbesartan or atenolol for 12 weeks; a diuretic and a calcium antagonist was added when needed thereafter in order to obtained a blood pressure below 140/90 mm Hg. All analyses were performed central in a core laboratory.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- At least 18 ys old
- Male or female with no child bearing potential
- Seated blood pressure diastolic 90-115 mm Hg
- Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women
- Informed consent
Exclusion criteria
- Coronary artery disease, heart failure or other significant cardiac disorder
- Cerebrovascular accident within the past 6 months
- A seated systolic blood pressure above 200 mm Hg
- Significant renal disease, collagen or vascular disease, or gastrointestinal condition
- Significant allergy or intolerance to study drug
- Alcohol or drug abuse
- Uncontrolled diabetes mellitus
Trial design
Primary purpose
Allocation
Interventional model
Masking
115 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal